Stay updated with breaking news from Scheie Eye. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.
A recent clinical trial, BRILLIANCE demonstrated the safety and efficacy of CRISPR gene editing in treating inherited blindness caused by mutations in the CEP290 gene.
BRILLIANCE trial results showed 11 out of 14 treated participants experienced some improvements in vision and quality of life measures. CRISPR-based therapy
Alicia Gresham, senior vice president and COO of Mount Sinai Health System, has been named CEO of Pennsylvania Hospital, part of Philadelphia-based Penn Medicin
The year's cohort of six recipients include a journalist, an astrophysicist, and Nobel Prize winners.